Merck & Co Inc
NYSE: MRK
$96.61
+$0.30 (+0.3%)
Real Time Data Delayed 15 Min.
MRK Articles
One key consideration for the year ahead is that Johnson & Johnson raised its dividends again and managed to have upside performance above what was expected.
Published:
thinkstockJanuary 7, 2015: Markets opened higher on Wednesday after ADP and TrimTab reports on unemployment came in a shade above expectations. The U.S. trade balance improved in November primarily...
Published:
Last Updated:
A new resort from UBS highlights the firm's first Equity Focus list for 2015. Here are five of the highest yielding dividend stocks on the list.
Published:
Monday's top analyst upgrades, downgrades and initiations include Akamai Technologies, Carnival, Chevron, El Pollo Loco, Ford, F5 Networks, Lululemon Athletica and Starbucks.
Published:
In a new research report, the SunTrust Robinson Humphrey team highlights the top pharmaceutical stocks to buy for 2015.
Published:
With investors loving dividends so much, 24/7 always tries to take a look at what the Dogs of the Dow will look like for the year ahead.
Published:
24/7 Wall St. has compiled a list health care stocks that Merrill Lynch expects to be top performers in 2015.
Published:
Last Updated:
thinkstockDecember 15, 2014: Markets opened higher on Monday following a strong report on industrial production that was later describe as a catch-up phase from previous growth. But the big drag...
Published:
Last Updated:
thinkstockDecember 9, 2014: Markets opened lower on Tuesday following a sharp decline overnight in the Shanghai Composite after China’s central bank tightened up liquidity restrictions. A better...
Published:
Last Updated:
SunTrust Robinson Humphrey analysts say in a research note that Achaogen and Cempra could be in play as acquisition targets.
Published:
Merck will acquire Cubist for $102 a share, or, about $9.5 billion, including $1.1 billion in Cubist’s net debt and other items.
Published:
Last Updated:
Monday may have started out as a fairly quiet news day for most stock sectors on a shortened week, but don't tell that to the Ebola drug stocks.
Published:
For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.
Published:
Last Updated:
thinkstockNovember 14, 2014: Markets opened mixed on Friday following a jump in U.S. consumer sentiment coupled with better-than-expected reports on eurozone GDP. Even oil is performing better today,...
Published:
Last Updated:
A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand for the drugs they produce that treat hepatitis C.
Published: